Kolomecki K, Stepien H, Bartos M, Kuzdak K
Clinic of Endocrinological and General Surgery, Medical University of Lodz, 93-513 Poland.
Endocr Regul. 2001 Mar;35(1):9-16.
To estimate serum levels of vascular endothelial growth factor (VEGF), metalloproteases MMP-2 (gelatinase A), MMP-3 (stromyelisine 1) and metalloprotease tissue inhibitors (TIMP-2) in patients with various benign and malignant adrenal tumours before and after surgery, as well as to evaluate if there is a correlation between serum levels of these agents and tumour types.
Serum levels of VEGF, MMP-2, -3 and TIMP-2 were estimated in 43 patients with adrenal tumour at the admission and, in case of surgery, again one month after surgery. The patients were divided into 6 groups according to the type of the tumour (I - patients with adrenal cortex carcinoma, II - with benign hormonally active adrenocortical adenomas, III - with benign, hormonally inactive adenocortical adenomas (incidentaloma), IV - with benign, hormonally active phaeochromocytomas, V - with hormonally quiescent phaeochromocytomas, VI - hormonally inactive adrenal tumours of extraglandular origin. The control group consisted of 10 healthy individuals.
There was no correlation between MMP-2 serum levels and tumour types and no significant difference between MMP-2 level before and after surgery. There were no significant differences between TIMP-2 serum levels in patients with adrenal tumours and the control values. Significant increase of serum MMP-3 level was found in patients with cortex cancer and hormonally active benign adrenocortical tumours. The MMP-3 mean serum level was also significantly higher in patients with malignant incidentalomas than in those with benign ones. In all groups of patients with adrenal tumours the means serum VEGF level was significantly higher than in control patients, and it was also significantly higher in patients with malignant incidantalomas than in those with benign ones. After surgery the VEGF level decreased significantly in patients with extraglandular tumours and cortex cancers who had no recurrence.
Since MMP-3 and VEGF serum levels were found significantly higher in patients with malignant adrenal incidentalomas than in those with benign ones, they might be applied as markers of malignancy of incidentalomas. VEGF and MMP-3 levels decreased after tumour resection in all patients with malignant tumors and increased significantly in patients with recurrence. Therefore, they are supposed to be of prognostic value in these patients.
评估各类良性和恶性肾上腺肿瘤患者手术前后血清血管内皮生长因子(VEGF)、金属蛋白酶MMP - 2(明胶酶A)、MMP - 3(基质溶解素1)及金属蛋白酶组织抑制剂(TIMP - 2)的水平,并评估这些因子的血清水平与肿瘤类型之间是否存在相关性。
对43例肾上腺肿瘤患者入院时测定血清VEGF、MMP - 2、 - 3及TIMP - 2水平,若接受手术,则在术后1个月再次测定。根据肿瘤类型将患者分为6组(I组 - 肾上腺皮质癌患者;II组 - 良性有激素活性的肾上腺皮质腺瘤患者;III组 - 良性无激素活性的肾上腺皮质腺瘤(偶发瘤)患者;IV组 - 良性有激素活性的嗜铬细胞瘤患者;V组 - 无激素活性的嗜铬细胞瘤患者;VI组 - 腺外起源的无激素活性肾上腺肿瘤患者)。对照组由10名健康个体组成。
MMP - 2血清水平与肿瘤类型之间无相关性,手术前后MMP - 2水平无显著差异。肾上腺肿瘤患者的TIMP - 2血清水平与对照值之间无显著差异。皮质癌患者及有激素活性的良性肾上腺皮质肿瘤患者血清MMP - 3水平显著升高。恶性偶发瘤患者的MMP - 3平均血清水平也显著高于良性偶发瘤患者。在所有肾上腺肿瘤患者组中,血清VEGF平均水平显著高于对照患者,恶性偶发瘤患者的血清VEGF水平也显著高于良性偶发瘤患者。无复发的腺外肿瘤和皮质癌患者术后VEGF水平显著下降。
由于恶性肾上腺偶发瘤患者的MMP - 3和VEGF血清水平显著高于良性偶发瘤患者,它们可能作为偶发瘤恶性程度的标志物。所有恶性肿瘤患者肿瘤切除后VEGF和MMP - 3水平下降,复发患者则显著升高。因此,它们在这些患者中应具有预后价值。